ClinicalTrials.gg
CompletedNCT06570928DAZACANNUpdated May 25, 2025

Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease

A Phase 2 interventional study of Cannabis and Placebo in Alzheimer Disease, sponsored by Federal University of Latin American Integration. Completed at 1 site in Brazil. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Federal University of Latin American Integration · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Alzheimer Disease with a site in Brazil — 13 open to participants now, 18 under way, 13 of them phase 3. Alzheimer Disease · Brazil.

Enrollment
39th of 55
72 · median 490
Started
2024
with 2 others
Phase 2
5 of 59
none open now
Registered
46th of 59
by date
Lead sponsor
2 of 59
Federal University of Latin American Integration

Among the 59 studies in Alzheimer Disease with a site in Brazil, this one is the 39th largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 in phase 2, and was the 46th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

13 of the 59 studies in Alzheimer Disease with a site in Brazil are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Alzheimer Disease with a site in Brazil, or all of them as a file.
02

Study summary

Brief Summary:

The objective of the study is to evaluate the effect of cannabinoids on Alzheimer's Disease. This is a double-blind, randomized, placebo-controlled clinical trial. The study aims to recruit patients of both sexes diagnosed with Alzheimer's Disease who are in the mild and moderate stages for treatment with cannabinoids.

The specific objectives of the study are:

Primary Outcome

  • To evaluate the effect of Cannabis sativa at low doses according to the Mini-Mental State Examination (MMSE) scale - Memory and Cognition test - in patients with Alzheimer's Disease.

Secondary Outcomes

  • To evaluate the effect of Cannabis sativa at low doses according to the Cornell scale - Depression in dementia test.
  • To evaluate the effect of Cannabis sativa at low doses according to the GDS scale - Depression in elderly people test.
  • To evaluate the effect of Cannabis sativa at low doses according to the QoL scale - Quality of Life test.
  • To evaluate the effect of Cannabis sativa at low doses according to the Epworth scale - Drowsiness test.
  • To evaluate the adverse effects of Cannabis sativa at low doses given daily for 26 weeks in patients with Alzheimer's Disease.

Participants will use a compound containing CBD/THC 50/5 mg/mL, administered as 0.2 mL once a day. The placebo group will use a compound identical to the treatment but containing only vehicle. To address the questions above, the treated group will be compared with the placebo group over a period of 6 months. Participants will be assessed every 2 months. Additionally, blood and cerebrospinal fluid tests will be conducted to measure specific proteins related to Alzheimer's Disease and inflammatory markers.

Read the detailed description

Alzheimer's disease (AD) is closely linked to the accumulation of neurotoxins derived from Aβ and tau, leading to cognitive impairment. This project posits that an imbalance in the endocannabinoid system occurs in an AD-dependent manner. Reported connections between dementia, inflammation, Aβ, and alterations in the cannabinoid system in experimental models of AD support this hypothesis. Cannabinoids may restore baseline brain function while avoiding major side effects. Despite extensive research into new AD therapies, no significant improvement has been achieved recently, and there is little consensus on how scientists will innovate to develop a new treatment. Cannabinoid-based therapy has emerged as crucial for the treatment of many diseases considered incurable. The expected results of this project will provide important insights into the ability of cannabinoids to counteract neurochemical imbalance during AD progression, thereby improving memory performance and affecting inflammation as well as Aβ and tau levels.

The key point is to provide evidence that cannabinoids can serve as an efficient treatment for AD while avoiding major side effects. The aim of this project is to determine the effect of cannabinoids in AD patients, evaluating memory and cognition. It is expected that the results will establish that cannabinoids are critical for restoring the baseline function of the endocannabinoid system in AD brains and their beneficial effects. This project may be instrumental in validating new therapeutic approaches for AD.

To evaluate the pharmacological activity of low doses of CBD, a double-blind, randomized, placebo-controlled clinical trial will be conducted for a duration of 6 months. A baseline assessment will be performed, and patients will be evaluated every 60 days for a period of 6 months, totaling 4 evaluation sessions. For this purpose, the following questionnaires will be applied: Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Geriatric Depression Scale (GDS), Alzheimer's Disease Quality of Life version patient, version caregiver and caregiver-patient version, Cornell Depression in Dementia Scale, and Epworth Sleepiness Scale. All questionnaires are references in their assessment domains and are validated for Portuguese/Brazil. In addition to the evaluation scales, biological material will be collected with blood and cerebrospinal fluid samples at baseline and at the end (after 6 months). The following analytes will be measured in the CSF: BDNF, beta-amyloid, Tau protein, TNFα, IL-6, IL-1β, and IL-10. During the research and data collection, patients' conventional treatments will not be altered.

Statistical Analysis Plan SPSS software, version 29.0 will be used for the analyses. For quantitative data, the Shapiro-Wilk distribution test will be performed. Potential associations between qualitative variables will be analyzed using the Chi-Square test with adjusted residual analysis (χ²). The means (±SD) will be analyzed using the Student's t test for independent samples. Medians [IQR] will be calculated using the Mann-Whitney U test. Paired quantitative data will be compared individually by group across the analyzed time points using Friedman's ANOVA test.

A generalized estimating equations (GEE) model, linear or with log-gamma link, and Bonferroni correction will be used to simultaneously evaluate quantitative parameters over time and between groups. For these descriptive analyses, data will be presented as means ± standard errors (±SEM). Pearson or Spearman correlations can be performed between variables of interest. For all analyses, the significance level will be set at 5%.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Alzheimer Disease
  • Cannabinoids
  • Cannabidiol
  • Tetrahydrocannabinol (THC)
  • Nervous System Diseases
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be over 60 years old;
  • Have been diagnosed with AD at least 1 year ago;
  • Present mild to moderate symptoms of AD.

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of other dementias or factors correlated;
  • Present psychosis or first-degree relatives with a history from psychosis, schizophrenia, epilepsy;
  • Individuals with a history of psychoactive substance abuse will be included in the study;
  • Present severe symptoms of AD.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Placebo comparator
    Placebo arm

    Patients will receive a liquid solution only with vehicle and no cannabinoid.

    Other: Placebo

  • Experimental
    Experimental arm

    Patients will receive the dose of 0,2 ml of a compound contain CBD:THC (50 mg:5 mg).

    Other: Cannabis

Interventions

  • OtherCannabis

    0,2 ml of CBD:THC (50 mg:5 mg)

    Also known as: CBD:THC (50 mg:5 mg)

  • OtherPlacebo

    Product vehicle, medium chain triglycerides (MCT)

06

What researchers measure

Primary outcomes

  1. Mini Mental State Exam (MMSE)

    scores range from 0 to 30, with higher scores indicating cognitive improvement.

    Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.

Secondary outcomes

  1. Neuropsychiatric Inventory-Questionnaire (NPI-Q)

    Assesses neuropsychiatric symptoms in patients with dementia. Evaluates 12 symptoms in the following domains: delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behaviors, nocturnal behavioral disorders, and appetite disorders. The score ranges from 0 to 144.

    Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.

  2. Geriatric Depression Scale (GDS)

    Assesses depressive symptoms in the elderly. The investigators will use the short version, which has a score from 0 to 15. The higher the score, the greater the depressive symptoms.

    Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.

  3. Quality of Life in Alzheimer's Disease scale (QoL-AD)

    The scale has 3 versions, one of which is applied to the patient, another to the caregiver to answer about the patient's life, and one for the caregiver to answer about their own life. The score may vary, the one the investigators will use is the sum of the questionnaires about the patient, caregiver version and patient version, with the patient version having a weight of 2. Its score varies from 13, indicating the worst possible quality of life, up to 52, and the higher the score, the higher the quality of life.

    Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.

  4. Cornell Scale for Depression in Dementia (CSDD)

    Assess symptoms of depression in patients with dementia. Has 19 questions applied to caregiver and patient. The maximum score is 38 points, with scores higher than 10 indicating probable major depression and greater than 18 as major depression.

    Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.

  5. Epworth Sleepiness Scale (ESS )

    Evaluates 8 items with scores ranging from 0 to 24, in which scores higher than 10 indicate sleep disturbances.

    Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.

  6. Specific markers of Alzheimer's disease: Beta-amyloid 40, beta-amyloid 42, tau protein (fraction 181), and phosphorylated tau protein

    The following proteins will be quantified in the cerebrospinal fluid: beta-amyloid 40, beta-amyloid 42, tau protein (fraction 181), and phosphorylated tau protein.

    Time frame: Collections will be made at the initial time, before the start of treatment and at the end time, after 180 days.

  7. BDNF (Brain Derived Neurotrophic Factor)

    It will be measured in serum or plasma

    Time frame: Collections will be made at the initial time, before the start of treatment and at the end time, after 180 days.

  8. Inflammatory markers: TNFα (Tumor Necrosis Factor alpha), IL-6 (Interleukin-6), IL-1β (Interleukin-1 beta), and IL-10 (Interleukin-10)

    It will be measured in serum or plasma

    Time frame: Collections will be made at the initial time, before the start of treatment and at the end time, after 180 days.

Other outcomes

  1. Safety Endpoints - UKU Side Effect Rating Scale

    Will be conducted on patients and caregivers during all planned visits to ascertain the frequency and severity of adverse events. There will be neurological and physical examinations as well as laboratory testing.

    Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.

07

Study locations

1 site
  • Federal University of Latin American Integration
    Foz do Iguaçu, Paraná 85870-650, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Aug 2024, 0 months.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's 0 months is below that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 26, 2024
StartActual
Aug 13, 2024
Primary completionActual
Aug 27, 2024
CompletionActual
Mar 27, 2025
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06570928
Lead sponsor
Federal University of Latin American Integration
Responsible party
FRANCISNEY PINTO DO NASCIMENTO (Professor and Coordinator of the Laboratory of Medicinal Cannabis and Psychedelic Science, Federal University of Latin American Integration) — Principal investigator
First posted
Aug 26, 2024
Start date
Aug 13, 2024
Primary completion
Aug 27, 2024
Completion
Mar 27, 2025
Last update
May 25, 2025

Study contacts

Taynara Silva, 1
principal investigator · Universidade Federal de Santa Catarina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion